Cannabis Clinical Trials

TORONTO, April 18, 2018 (GLOBE NEWSWIRE) — BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE:BLGV) (OTCQB:BLGVF) (“Belgravia” or the “Company”) has appointed Dr. Sam Hanna as Chief Medical Officer of its cannabis dermatology division.  Dr. Hanna is a well-recognized Canadian dermatologist with experience in numerous clinical studies for dermatology drugs across North America. Belgravia Dermatology Division – ICP […]

by

Tikun Olam, the world leader in cannabis science, and Ilera Healthcare, Pennsylvania’s premier medical marijuana cultivator, processor and dispenser, have finalized a deal to bring Tikun’s world-renowned medical marijuana strains to medical cannabis patients in the Keystone State later this year. This partnership combines Tikun Olam’s history of peer-reviewed scientific research and unprecedented clinical data […]

by

Sourcing sufficient quantities of these minor cannabinoids and terpenes is essential for providing the highest possible efficacy in GB Sciences’ PD formulations, but they are more difficult to procure in botanical form because they are in lower abundance in the cannabis plants. GB Sciences has been addressing these supply issues at its cultivation and extraction […]

by

PHILADELPHIA and NEW YORK, April 17, 2018 /PRNewswire/ — Tikun Olam, the world leader in cannabis science, and Ilera Healthcare, Pennsylvania’s premier medical marijuana cultivator, processor and dispenser, have finalized a deal to bring Tikun’s world-renowned medical marijuana strains to medical cannabis patients in the Keystone State later this year. This partnership combines Tikun Olam’s history […]

by

Pickens Mountain Marijuana Farm John Boehner joined the advisory board of a marijuana company, despite being anti-legalization when he was in the congress.  President Trump has confirmed a deal with Colorado Senator Cory Gardner to let Colorado make its own cannabis legalization decisions in exchange for the Senator not holding up Department of Justice nominations. […]

by

Zelda Therapeutics (ASX: ZLD) has gained Institutional Review Board approval to trial its cannabinoid-based formulations on children suffering from autism, which was the final regulatory hurdle to jump before beginning the study. The trial will be carried out at the Children’s Hospital of Philadelphia and involves observation and bioanalytical studies. “We are very excited to […]

by

Perth-based clinical trials company Zelda Therapeutics (ASX:ZLD) now has approval for their autism project involving cannabis to be conducted at the USA-based Children’s Hospital of Philadelphia. The Institutional Review Board Approval is the equivalent to Human Research Ethics Approval here in Australia. It essentially allows the planned study to commence within the parameters of the […]

by

OTTAWA, ONTARIO–(Marketwired – Apr 12, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (TBPMF), provides a status report on its encapsulated cannabis oils (PPP005) clinical trials and that these cannabis products are ready to commercialize in the retail market post-legalization. Natural health products and OTC medications The authorization from the Office of […]

by

OTTAWA, ONTARIO–(Marketwired – April 12, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF), provides a status report on its encapsulated cannabis oils (PPP005) clinical trials and that these cannabis products are ready to commercialize in the retail market post-legalization. Natural health products and OTC medications The authorization from the Office of […]

by

As previously reported, GB Sciences has pending US and International patent applications covering multiple, related PD-formulas based on complex mixtures of minor cannabinoids and terpenes from cannabis chemovars. In pre-clinical studies, these complex cannabis-based formulas both increased dopamine production and demonstrated potential neuroprotective properties. The disease processes targeted by GB Sciences’ therapeutic mixtures are central […]

by